cardiac sodium channel alpha subunit; cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit; CDCD2; CMD1E; CMPD2; HB1; HB2; HBBD; HH1; ICCD; IVF; LQT3; Nav1.5; PFHB1; SCN5A; Sodium channel protein cardiac muscle subunit alpha; Sodium channel protein type 5 subunit alpha; sodium channel protein type V alpha subunit; Sodium channel protein type V subunit alpha; sodium channel, voltage-gated, type V, alpha subunit; SSS1; VF1; Voltage-gated sodium channel subunit alpha Nav1.5

For Research Use Only. Not for use in diagnostic procedures.

IgM

4G8:1G7

Mouse

This antibody recognises sodium channel protein type 5 subunit alpha (SCN5A), which is also known as Nav 1.5. SCN5A, the major cardiac voltage-gated sodium channel, plays a central role in the generation of the cardiac action potential and in the propagation of electrical impulses in the heart.

Purified on protein G

Purified IgG supplied in Phosphate buffered saline (PBS) containing 0.09% Sodium azide

1mg/ml (lot specific)

Small volumes of anti-SCN5A antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Flow Cytometry (FC/FACS), Immunocytochemistry (ICC), Immunofluorescence (IF), Western Blot (WB)

Optimal antibody dilution should be determined by titration

224,917 Da

sodium channel, voltage gated, type V alpha subunit

sodium channel protein type 5 subunit alpha; cardiac tetrodotoxin-insensitive voltage-dependent sodium channel alpha subunit; sodium channel protein cardiac muscle subunit alpha; sodium channel, voltage-gated, type V, alpha subunit; voltage-gated sodium channel subunit alpha Nav1.5

Sodium channel protein type 5 subunit alpha

SCN5A_HUMAN

The protein encoded by this gene is an integral membrane protein and tetrodotoxin-resistant voltage-gated sodium channel subunit. This protein is found primarily in cardiac muscle and is responsible for the initial upstroke of the action potential in an electrocardiogram. Defects in this gene are a cause of long QT syndrome type 3 (LQT3), an autosomal dominant cardiac disease. Alternative splicing results in several transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]

SCN5A: an integral membrane protein and a voltage-gated sodium channel subunit. Mediates the voltage-dependent sodium ion permeability of excitable membranes. This protein is found primarily in cardiac muscle and is responsible for the initial upstroke of the action potential in an electrocardiogram. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. Intracellular calcium levels regulate channel inactivation. Interacts with the PDZ domain of the syntrophin SNTA1, SNTB1 and SNTB2. Interacts with NEDD4, NEDD4L, WWP2 and GPD1L. Defects in this protein are a cause of long QT syndrome type 3 (LQT3). Belongs to the sodium channel (TC 1.A.1.10) family, Nav1.5/SCN5A subfamily. 6 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, multi-pass; Membrane protein, integral; Channel, sodium

Chromosomal Location of Human Ortholog: 3p21

Cellular Component: voltage-gated sodium channel complex; cell surface; endoplasmic reticulum; T-tubule; integral to membrane; plasma membrane; caveola; lateral plasma membrane; sarcolemma

Molecular Function: calmodulin binding; protein binding; fibroblast growth factor binding; enzyme binding; ubiquitin protein ligase binding; voltage-gated sodium channel activity; ankyrin binding; nitric-oxide synthase binding; protein kinase binding

Biological Process: axon guidance; membrane depolarization; telencephalon development; regulation of heart rate; sodium ion transport; generation of action potential; cerebellum development; response to denervation involved in regulation of muscle adaptation; positive regulation of action potential; positive regulation of epithelial cell proliferation; odontogenesis of dentine-containing teeth; cardiac muscle contraction

Disease: Brugada Syndrome 1; Sudden Infant Death Syndrome; Ventricular Fibrillation During Myocardial Infarction, Susceptibility To; Sick Sinus Syndrome 1, Autosomal Recessive; Progressive Familial Heart Block, Type Ia; Long Qt Syndrome 3; Cardiomyopathy, Dilated, 1e; Atrial Fibrillation, Familial, 10

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.